血清TREM-1、sCD163及sB7-H3检测在原发性肝癌患者中的表达

摘要/Abstract

摘要： 目的探讨血清髓样细胞触发受体1(TREM-1)、可溶性CD163分子(sCD163)及可溶性B7-H3(sB7-H3)检测在原发性肝癌患者中的表达。方法收集2017年5月—2019年5月重庆市忠县人民医院就诊的110例原发性肝癌的临床资料,分为预后不良(死亡,n=45)和预后良好(存活,n=65)两组。比较两组患者基本资料,检测血清TREM-1、sCD163、sB7-H3水平。通过ROC分析血清TREM-1、sCD163、sB7-H3预测原发性肝癌患者预后不良的价值,并进行多因素logistic回归性分析。结果肿瘤大小≥5 cm、有肝硬化、有血管侵犯的占比及TREM-1、sCD163、sB7-H3水平均为预后不良组高于预后良好组(P<0.05);经ROC和logistic分析,肿瘤大小≥5 cm、有肝硬化、有血管侵犯、TREM-1≥3.625 ng/mL、sCD163≥1.520 μg/mL、sB7-H3≥425.670 pg/mL是原发性肝癌患者预后不良的危险因素(P<0.05)。结论 TREM-1、sCD163及sB7-H3检测在原发性肝癌预后中具有一定预测价值。

关键词: 髓样细胞触发受体1, 可溶性CD163分子, 可溶性B7-H3, 原发性肝癌

Abstract: Objective To explore the expressions of serum myeloid cell trigger receptor 1 (TREM-1), soluble CD163 molecule (sCD163), and soluble B7-H3 (sB7-H3) test in patients with primary liver cancer and their association with the patients' prognosis. Methods The clinical data of 110 cases of primary liver cancer treated in Zhongxian People's Hospital of Chongqing were collected. They were divided into a poor prognosis group (death, N=45) and a good prognosis group (survival, N=65). The basic information and the levels of TREM-1, sCD163 and SB7-H3 of the two groups of patients were detected. The value of serum TREM-1, sCD163 and SB7-H3 in predicting the poor prognosis of HCC patients were analyzed by receiver operating curve (ROC) and multivariate logistic regression analyses. Results The proportion of tumor size ≥5 cm, liver cirrhosis, vascular invasion, and TREM-1, sCD163, and sB7-H3 levels were all higher in the poor prognosis group than those in the good prognosis group (P<0.05). Tumor size≥5 cm, with liver cirrhosis, with vascular invasion, TREM-1≥3.625 ng/mL, sCD163≥1.520 μg/mL, and sB7-H3≥425.670 pg/mL were the risk factors for poor prognosis in primary HCC patients (P<0.05). Conclusion TREM-1, sCD163, and sB7-H3 tests may have value in predicting the prognosis of primary liver cancer.

Key words: Myeloid cells trigger receptor 1, Soluble CD163 molecule, Soluble B7-H3, Primary liver cancer

秦晓平, 张静, 艾平. 血清TREM-1、sCD163及sB7-H3检测在原发性肝癌患者中的表达[J]. 肝脏, 2023, 28(4): 461-464.

QIN Xiao-ping, ZHANG Jing, AI Ping. The expression of TREM-1, sCD163 and sB7-H3 in patients with primary liver cancer[J]. Chinese Hepatolgy, 2023, 28(4): 461-464.

参考文献

[1] 王儒阳, 吴思嘉, 佟静. 重视原发性肝癌的早期监测. 中国临床医生杂志, 2019, 47(12):1394-1397.
[2] Wu W, He X, Andayani D, et al. Pattern of distant extrahepatic metastases in primary liver cancer: A SEER based study. J Cancer, 2017, 8(12):2312-2318.
[3] 王瑛, 袁鹤立, 赵利, 等. 清热利胆自拟方对仑伐替尼联合卡瑞丽珠单抗治疗晚期原发性肝癌患者炎症因子,免疫细胞水平和生活质量的影响. 现代中西医结合杂志, 2021, 30(24):2664-2669.
[4] 赵和平, 于燕. sB7-H3、IL-17和IL-8对原发性肝癌的诊断效果. 中国现代医学杂志, 2018, 28(7):66-69.
[5] 中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝脏病杂志, 2015, 23(5):321-327.
[6] Czauderna C, Castven D, Mahn FL, et al. Context-dependent role of NF-κB signaling in primary liver cancer-from tumor development to therapeutic implications. Cancers, 2019, 11(8):1053.
[7] 李广云, 陈政华, 徐逢皇, 等. 肝癌患者血清中共刺激分子sB7-H3和炎症因子IL-17、IL-8相关性及临床诊断研究. 中华微生物学和免疫学杂志, 2016, 36(3):213-218.
[8] Dai T, Peng L, Lin G, et al. Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma. J Gastrointest Oncol, 2019, 10(6):1049-1063.
[9] Daiku K, Fukuda K, Morimoto O, et al. Primary adenosquamous carcinoma of the liver detected during cancer surveillance in a patient with primary sclerosing cholangitis. Clin J Gastroenterol, 2020, 13(6):1273-1279.
[10] 王刚, 高泉根, 沈根海. 影响原发性肝癌患者手术治疗预后的危险因素分析. 中华肿瘤防治杂志, 2018, 25(S1):85-86.
[11] 孔德帅, 袁俊建, 陈雄飞, 等. 宽切缘根治切除治疗伴微血管侵犯的原发性肝癌患者预后及原发性肝癌手术患者短期预后影响因素分析. 临床误诊误治, 2019, 32(7):85-88.
[12] 杨培, 曾新桃, 罗华, 等. 解剖性肝切除术治疗原发性肝癌合并微血管侵犯患者的复发情况及其影响因素分析. 临床和实验医学杂志, 2021, 20(16):1727-1730.
[13] 潘薇, 陈瑞, 张忠涛. TREM-1和HMG B1在老年直肠癌患者肿瘤组织中的表达及其与预后的关系. 中国现代普通外科进展, 2019, 22(5):378-380,385.
[14] Kazankov K, Rode A, Simonsen K, et al. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. Scand J Clin Lab Inv, 2016, 76(1):64-73.
[15] 刘炼玲, 李勇. 血清AFP-L3,CYFRA21-1及sB7-H3对原发性肝癌患者近期疗效及预后的预测价值. 中西医结合肝病杂志, 2021, 31(6):502-505.